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Isolation of the Viral  Complement  (C1) Receptor and Identification as 
pl5E* 
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(From the Department of Molecular Immunology, Research Institute of Scripps Clinic, La Jolla, 
California 92037) 
Human serum inactivates RNA tumor viruses as Welsh and co-workers (1-4) 
have demonstrated.  The mechanism of inactivation was shown to be comple- 
ment-mediated viral lysis,  not requiring virion-specific antibodies.  All C-type 
RNA  viruses  were lysed  by  sera  from primates  but  not from rabbits,  mice, 
guinea pigs,  or goats.  Cooper  et al.  (4) showed that integrity of the classical 
complement  sequence  was  an  absolute  requirement  for  lysis  and  that,  in 
absence of specific antibody, Clq  I subserved the virus recognition function. The 
antibody independent nature of  this virolytic reaction suggests that complement 
plays an important role in natural or nonspecific defense against C-type RNA 
viruses. We have therefore explored the envelope proteins of Moloney leukemia 
virus as to their capacity to activate complement, and have identified a single, 
low molecular weight surface protein as the viral receptor and activator of C1. 
Materials and Methods 
Chemicals and Reagents.  Trypsin,  soy bean trypsin  inhibitor,  chymotrypsinogen,  RNase, 
cytochrome c, phospholipase A, sodium barbital; Tris, and cyanogen bromide were obtained from 
Sigma Chemical Co. (St. Louis, Mo.). Ampholines (Servalyt T4-9) were purchased from Accurate 
Chemical & Scientific Corp.  (Hicksville, N.  Y.),  Pevikon C-890 from Mercer Consolidated Corp. 
(Yonkers, N.  Y.), and ~2~I-Na and 131I-Na from New England Nuclear (Boston, Mass.). 
Complement Components and Complement Reagents.  Fresh human serum (Community Blood 
and Plasma, San Diego, Calif.) and fresh guinea pig serum frozen at -70°C were used as a source 
of complement. Zymosan (Nutritional Biochemicals Corp., Cleveland, Ohio) was boiled for 1 h at 
a  concentration of 100 mg/ml and stored suspended in saline. Human sera were depleted of both 
Clq and C7 by immunoadsorption. 2 Factor B-deficient serum was provided by Dr.  R.  schreiber 
and C3~ by Dr. T. Hugli both at Scripps Clinic. C7 was isolated as described earlier (5), and Clq 
was isolated by the method of Yonemasu and Stroud (6). 
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Viruses, Viral Proteins, and Antisera.  Moloney (M-MuLV), Rauscher (RoMuLV), AKR (AKR- 
MuLV), and NZB xenotropic (X-MuLV) murine leukemia viruses (prepared by Electro Nucleonics 
Inc.,  Bethesda,  Md.)  were  supplied  by  the  Office of Program  Resources  and  Logistics,  Viral 
Oncology, National Cancer Institute.  Antisera against these viruses and against the major viral 
proteins gp70, p30, p12, and pl0 (prepared by Huntington Research Center, Baltimore, Md.) were 
also furnished by this office. Rat leukemia virus strain BN-p454-9 (Ra-LV) was a gift from Dr. F. 
C.  Jensen,  Scripps  Clinic,  gp70  and  p30  from R-MuLV and  AKR-MuLV were  isolated by the 
method of Strand and August (7). 
Complement  Activation Assays.  Activation of human complement was measured by conver- 
sion of C1 to C1 (8) and the formation of C5b-9,  the end product of both complement pathways. In 
the latter test, to be described in detail elsewhere,  3 C7-depleted human serum reconstituted with 
purified ~25I-C7 (C7 reagent) formed a stable radiolabeled C5b-9 complex upon activation. To test 
for complement  activation,  100  ~l  of C7  reagent  was  added  to  50  /~l of the  test  sample  and 
incubated for 45 rain at 37°C. 100 ~l of the reaction mixture was then layered on a 50-~1 cushion of 
15% sucrose in a 175-~1 nitrocellulose centrifuge tube and centrifuged for 90 rain at 160,000 gmax in 
an  air-driven  ultracentrifuge  (Airfuge,  Beckman  Instruments,  Inc.,  Spinco  Div.,  Palo  Alto, 
Calif.). After the supernate was withdrawn into tissue paper, the total radioactivity of the pellet 
was determined.  For each test,  C7 reagent containing Zymosan as a  complement activator was 
used as a  standard  for maximal activation. In this sample, usually 35% of the C7 radioactivity 
was recovered in the form of labeled C5b-9. 
Complement  Consumption.  Samples being tested  for their  ability to consume  complement 
were incubated for 30 min at 37°C and then titrated for remaining activity by standard  methods 
(9). 
Radioiodination.  Proteins and viruses were trace labeled with ~25I or lalI by using the solid- 
phase  lactoperoxidase  procedure  of David  and  Reisfeld  (10). Bovine lactoperoxidase  bound  to 
Sepharose 4B was kindly provided by Dr. G. David, Scripps Clinic. 
Sucrose Density Gradient  Centrifugation.  Samples were sedimented at 4°C in linear sucrose 
gradients (prepared in 10 mM Tris, 100 mM NaC1, 1 mM EDTA [TNE])  4 in an SW 50.1 rotor using 
a L3-50 ultracentrifuge (Beckman Instruments,  Inc., Fullerton, Calif.). Times and gravity forces 
are noted in respective figure legends. 
Electron  Microscopy.  Virus preparations  were negatively stained with phosphotungstic  acid 
without  prior  fixation  and  examined  and  photographed  in  a  Hitachi  llE  electron  microscope 
(Hitachi Ltd., Tokyo, Japan) at 75 kV at a  direct magnification of 36,000. 
Sodium  Dodecyl  Sulfate-Polyacrylamide  Gel Electrophoresis  (SDS-PAGE).  Electrophoresis 
was carried out in 10-cm long gels containing 0.1% SDS and 15% polyacrylamide according to the 
procedure of Weber and Osborne  (11). After electrophoresis, bands were visualized by staining 
with Coomassie Brilliant Blue R-250, or sliced into equal segments and analyzed for radioactivity. 
Hemagglutination Inhibition Assays.  The C5b-9 content in samples  from sucrose gradients 
was estimated from the degree of inhibition of agglutination of EAC1-7 by antiserum to C5b-9- 
specific neoantigens (12). 
Digestion  Studies.  Protein digestions were carried out at a final trypsin concentration of 1% 
(weight/weight protein) whereas for viral digestions, 10% trypsin (weight/weight virus) was used. 
After incubating  the  mixtures  for 1 h  at  25°C,  the reaction was  terminated  by adding excess 
soybean trypsin inhibitor. Digestion with cyanogen bromide was performed in 70% formic acid at 
room temperature for 24 h followed by lyophilization of the samples to dryness. 
RDDP  5 Release Assay.  The assay,  which measures  incorporation of [3H]TMP  into (dT)12-1~- 
(rA)  n catalyzed by the virion's reverse transcriptase,  was performed as described in reference 1. 
Isoelectric  Focusing.  Isoelectric  focusing  (IEF)  was  carried  out  in  a  granulated  support 
mixture (48 g Pevikon, 2.5 g Sephadex G-75) as described by Otavsky et al. (13) in the presence of 
2% ampholines (pH range 4-9) and 0.2% Triton X-100.  Usually 1-2 mg of virus was disrupted in 
1% Triton X-100  in TNE at room temperature  and,  after centrifuging for 10 rain at 160,000 g  to 
3 R. M. Bartholomew, E. R. Podack,  and A. F. Esser.  Manuscript in preparation. 
4  Abbreviations used in this paper:  IEF, isoeleetric focusing; PAGE, polyacrylamide gel elec- 
trophoresis; PBS, phosphate-buffered saline; SDS, sodium dodecyl sulfate; TMP, ribosylthymine 
5'-monophosphate; TNE, 10 mM Tris, 100 mM NaC1,  1 mM EDTA pH 7.0. 
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FIG.  1.  Formation of C5b-9 by M-MuLV. Normal human serum (0.2 ml) containing 125I-C7 
(105 cpm) was incubated with 5 mg zymosan (©) or 5 /~g M-MuLV (Q) for 45 rain at 37°C. 
The  mixtures  were  applied  to  10-40%  linear sucrose  gradients  (prepared  in  TNE)  and 
centrifuged for 16 h  at 125,000 gmax- C5b-9 formed in the zymosan sample sedimented at a 
density of 1.12 g/cm  3, and C5b-9 formed in the virus-activated sample sedimented in a lower 
density region.  The latter was  identified by inhibition of complex-neoantigen-dependent 
hemagglutination (stippled area).  Direction of sedimentation is towards the left. 
remove particulate material, was made 2% in ampholines and applied to the center of the Pevikon 
bed in a volume not exceeding 2 ml. IEF was performed at a 6-W constant power until the voltage 
reached 400 V, and then continued at constant voltage overnight. The gel bed was fractionated 
into 30 equal segments and the pH of each segment was measured directly using a special surface 
electrode  (Microelectrodes,  Inc.,  Londonderry,  N.  H.).  When  monitoring  radioactivity,  we 
analyzed each segment before attempting to remove the Pevikon. The Pevikon was removed, and 
each  sample  was  freed  of ampholines  and  neutralized by  dialysis  against phosphate-buffered 
saline (PBS) containing 0.1% Triton X-100. 
Results 
Formation of the C5b-9 Complex on the Viral Surface.  The cytolytic entity 
formed by both activation pathways is the C5b-9 complex. Previous work (14) 
demonstrated  that  human  serum  containing  125I-C7 upon  incubation  with 
zymosan formed a  soluble radiolabeled C5b-9 complex.  C5b-9 formed by viral 
activation,  unlike  the  complex formed by zymosan  activation,  is  not  free  in 
solution. During rate zonal centrifugation the complex detected by hemaggluti- 
nation inhibition  assay sediments more slowly than free C5b-9 or intact virus. 
From  its  location  in the  sucrose density gradient  the  complex appears  to be 
attached to lipid-rich viral membrane fragments produced during lysis (Fig. 1). 
The characteristic ultrastructural  lesions associated with the membrane-bound 
C5b-9 complex as well as the disintegration process of the virus after comple- 
ment attack can be seen in the electron micrographs shown in Fig. 2. 
Virus Activates both Complement Pathways.  In addition to classical path- 
way activation  we found activation  of the  alternative  pathway by the virus. 
When Clq-depleted serum was used, some C5b-9 formation was observed at the 
highest virus concentration  (Fig. 3). Since incubation with aggregated IgG did 
not form C5b-9, complex formation did not result from residual C1 activation. 
Saturation  of viral  C1 receptors with purified Clq did not completely prevent 
lysis unless the serum was depleted of factor B. These results indicate that M- 
MuLV can activate both pathways but because of more efficient activation, the 
classical pathway predominates in the virolytic reaction. R.  M.  BARTHOLOMEW,  A.  F.  ESSER,  AND  H.  J.  MULLERoEBERHARD  847 
FIG.  2.  Electron microscopic appearance of Ra-LV strain BN-1454-9 before (A) and after 
(B)  incubation  with  human  serum.  Virus  preparations  were  negatively  stained  with 
phosphotungstic  acid  without  prior  fixation  and  examined  in  a  Hitachi  llE  electron 
microscope at a direct magnification of 36,000. Bar corresponds to 100 nm. Arrows indicate 
typical complement lesions. 
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FIG.  3.  Activation of classical and alternative  pathway of complement by M-MuLV. 100 
/~l of C7 reagent  (0) and Clq-deficient C7 reagent (©) were incubated with the indicated 
number  of virions.  Virus counts of the undiluted  sample had been determined  electron 
microscopically by the supplier (Electro-Nucleonics Inc.). 
Complement Activation  by Disrupted  Virus.  Before purification of the viral 
complement receptor could be attempted it was necessary to show that disrupted 
virus  retains  the  ability  to  activate  the  complement  system.  Since  C5b-9 
formation is insensitive to 1% Triton X-100 we used C5b-9 formation to test the 
ability  of detergent  disrupted  MuLV  to  activate  complement.  Disrupted  M- 
MuLV activated complement and the responsible material was recovered in the 
supernate after centrifugation at 160,000 gz,x for 10 min. 
Isolation  of the Viral Complement Activator.  Moloney leukemia virus was 848  C1  RECEPTOR  ON  ONCORNAVIRUSES 
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FIG. 4.  SDS-PAGE radioactivity distribution of labeled M-MuLV. Using solid-phase 
lactoperoxidase and 500 ~Ci 131I, 100 ~g of freshly thawed virus were labeled at 4°C and 
purified by gel filtration and sucrose density gradient centrifugation.  A 20-/~1 sample was 
denatured in the presence of 1% SDS and 1% B-mercaptoethanol  ,and analyzed on 15% 
polyacrylamide  gels (A). Triton X-100-disrupted virus, labeled  with ~2~I, was included  in the 
same gel to identify viral proteins. The latter are named according to the convention of 
August et al. (15) (B). 
surface labeled with 1~1I by solid-phase lactoperoxidase and then banded in a 
20-65%  sucrose density gradient to separate intact virions from other labeled 
components.  As  shown by  SDS-PAGE  analysis, banded material completely 
lacked radioactivity in the internal p30  viral protein  (Fig.  4),  demonstrating 
that only components at or near the viral surface had become labeled. Two main 
peaks of radioactivity were apparent,  one corresponding to the 68,000-dalton 
glycoprotein and the other to a protein of ----15,000 daltons. 
To  purify the  viral  receptor  the  surface  labeled  and  disrupted  virus  was 
subjected to IEF in a Pevikon-Sephadex mixture in the presence of Triton X-100 
(Fig. 5 A).  Two peaks of radioactivity were detected. Analysis by SDS-PAGE 
identified the peak at pH 5.3 as a 68,000-dalton protein, and the peak at pH 7.5 
as a low molecular weight protein. IEF of a sample of M-MuLV disrupted before 
labeling  yielded  additional  peaks  of radioactivity  (data  not  shown).  After 
removing Pevikon and ampholines, each fraction was tested for its ability to 
cause C5b-9  formation in C7  reagent.  Only one discrete peak of activity was 
noted which coincided with the pH  7.5  peak  of radioactivity (low  molecular 
weight protein)  (Fig.  5  B).  Several  such  focusing experiments  consistently 
yielded only one discrete band of activity, with a  pI ranging from 7.4 to 7.8, 
always coinciding with the smaller radioactivity peak. Formation of C5b-9 was 
a  result of activation of the classical pathway, because the protein at pH 7.5 
showed  strong  affinity for  Clq  in  sucrose  density  gradient  centrifugation 
experiments (data not shown) and converted C1 to Ci very efficiently (Fig. 6), 
whether or not Triton X-100 was present in the assay. In contrast, activation of R.  M.  BARTHOLOMEW,  A.  F.  ESSER,  AND  H.  J.  M~LLER-EBERHARD  849 
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FIG. 5.  Localization  of  complement-activating ability  to a protein  with pI 7.5.  Surface- 
labeled,  sucrose  density-banded,  virus  was disrupted  in 1% Triton  X-100 and centrifuged  at 
160,000  gmax  for  10  rain.  The supernate was  then  subjected  to  IEF  in  Pevikon/Sephadex  G-75 
containing  0.2% Triton  X-100 and 2% ampholines (pH 4-9).  After  division  of  the  bed  into  30 
equal segments, pH and radioactivity  of  each segment were determined (A).  The carrier 
material was removed by filtration,  and each fraction  was neutralized and freed of 
ampholines  by dialysis  against PBS containing 0.1% Triton X-100. The ability  of each 
fraction  to form C5b-9 was then determined (B). 
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FIG. 6.  Conversion of  C1 to Ci by the  viral  activator.  The fraction  at  pH 7.5  ofFig. 5  was 
isolated,  dialyzed  and freed  of  Triton X-100 by passage through SM-2 Bio-Beads (Bio-Rad 
Laboratories,  Richmond, Calif.).  One-half  of  the  sample (50 pl)  was then incubated with 50 
pl of  C1 containing 1251-Cls  for 30 min at  37°C in the absence (A) or in the presence (B)  of 
0.1% Triton X-100.  Under these conditions  activation  of  C1 results  in proteolytic  cleavage 
of  Cls to  form C1§. The labeled,  heavy chain (CI§H)  of  C1§ can be identified  by SDS-PAGE 
under reducing conditions.  (The light  chain of  Cli is  not  susceptible  to  radioiodination;  for 
further  experimental details  see reference  8). The extent  of  nov_specific  C1s conversion  by 
0.1% Triton  X-100 in buffer  is  shown in C. 
the alternative  pathway  required  intact virus,  since Triton  X-100-disrupted 
virus did not promote C5b-9 formation in Clq-depleted  serum  (not shown). 
Despite  the  cogency  of these  results,  the  possibility  remained  that  the 
complement-activating  property  resided  in  an  unlabeled  substance  with  a 
similar pI that was liberated during Triton X-100 disruption.  This possibility 850  C1  RECEPTOR  ON  ONCORNAVIRUSES 
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FIG. 7.  Characterization of purified viral  complement receptor  by  SDS-PAGE.  The 
dialyzed  receptor,  purified  by IEF from surface-labeled  M-MuLV, was labeled  with '2~I  (0) 
and then mixed with '3q-labeled,  disrupted  M-MuLV  (©).  Electrophoresis  was carried  out 
in  15% polyacrylamide gels  in  the presence  of  0.1%  SDS under  reducing conditions.  Unfixed 
gels  were sliced  into  0.7-mm segments. Note the absence  of  contaminating  proteins  in  the 
receptor  preparation. 
was precluded by the following results.  Incubating surface-labeled virus with 
trypsin released >70% of  the total  radioactivity,  without change in viral  density 
or release of  internal reverse transcriptase. This trypsin-digested, intact virus 
had completely lost  its  potential to  form C5b-9 and to convert CI to Ci. Activity 
was not restored when the trypsin-treated virus was disrupted with 1% Triton 
X-100 showing that internal components  could not initiate  the complement 
sequence. When the isolated  complement receptor was digested with trypsin its 
activity  was likewise lost,  yet incubation with RNAse, lipase,  or phospholipase 
A had no effect. 
That gp70 (the protein at pH 5.3) is not the viral  complement  receptor is 
supported further by the observations  that (a) several gp70 isolated from 
different  oncornaviruses by a different  method (7)  did not activate complement, 
(b) AKR-MuLV  that was stripped of  gp70 by repeated sucrose density centrifu- 
gation still  activated complement, and (c) noninfectious Ra-LV strain BN-1454- 
9 that lacks gp70 (F. Jensen, personal communication)  and the surface knobs 
characteristic  for  this  glycoprotein (see  Fig. 2A), can be lysed by human serum 
(2). 
Identification of the Viral Complement Receptor as p15E.  Isolated activator 
was labeled with  125I, mixed with  131I-labeled,  detergent-disrupted  virus,  and 
the  mixture  was analyzed  by SDS-PAGE.  Fig.  7 indicates  that  the  activator 
migrated  together  with  the  p15  complex  and  that  no  other  proteins  with 
different  molecular weight but identical  pI were present  in  this  preparation. 
When analyses were performed on slab gels in the presence of molecular weight 
markers,  the  mobility of the receptor was consistently found to be similar to 
that of p15. Treatment  of the receptor protein with cyanogen bromide cleaved 
the receptor (data not shown). These results strongly implicate pl5E (15) as the 
viral  complement receptor.  In  accordance with this  conclusion we found that R.  M.  BARTHOLOMEW,  A.  F.  ESSER,  AND  H.  J.  M~LLER-EBERHARD  851 
internal  M-MuLV p15  supplied  by  Dr.  J.  Ihle,  Frederick Cancer Research 
Center, Bethesda, Md., did not form C5b-9 at concentrations as high as 2 pg, 
whereas a p15 preparation from Moloney murine sarcoma virus (M-MuSV) pro- 
vided by Dr. G. Vande Woude, National Cancer Institute and recently charac- 
terized as a surface protein (16) did consume complement in human serum but 
not in guinea pig serum. 
In addition to Moloney virus, we have also tested Rauscher-MuLV, AKR- 
MuLV, and a xenotropic MuLV derived from NZB mice, and obtained similar 
results. 
Discussion 
Activation of the classical pathway of complement is  usually mediated by 
antigen-antibody complexes. In addition, several systems of classical pathway 
activation  independent  of antibodies  have  been  observed  (summarized  in 
reference 4).  In every case,  including the lysis of oncornaviruses by human 
complement, the recognition function is provided by the Clq subcomponent of 
C1. 
To  elicit lysis,  C1  must interact with the  viral envelope.  For this reason 
proteins, lipids, and carbohydrates might be involved in Clq recognition. Our 
studies indicate that a protein is necessary for activation. However, it is possible 
that the protein,  which we isolated by IEF  in the presence of detergent, is 
tightly associated with phospho- or glycolipids to form a proteolipid. Although 
such lipid moieties could provide the actual Clq-binding sites, several lines of 
evidence argue against this possibility: (a) lipase or phospholipase treatment 
did not abrogate activation; (b) a  surface protein from M-MuSV,  isolated by 
methods that would dissociate a proteolipid into its constituents (chromatogra- 
phy in 6 M guanidine hydrochloride and preparative SDS-PAGE), still showed 
activity, and (c) the lipid portion of oncornaviruses is derived from the host cell, 
yet all C-type RNA viruses were lysed regardless of the cell from which they 
were derived (2). 
Identification of the C1  receptor as one of the known viral proteins is not 
straightforward. Thus far, five proteins have been unequivocally identified as 
viral gene products (17): the major glycoprotein, gp70, the core protein, p30, an 
internal  phosphoprotein,  p12, an  RNA-binding  protein,  pl0,  and  another 
internal  protein,  p15. Furthermore, based  on  studies  of precursor proteins, 
there is good evidence for two other viral proteins in the R-MuL¥ system, pl5E 
and pl2E (18, 19). The former is derived from a precursor protein Pr2a + b by 
cleavage before virus maturation and the latter appears to be a  degradation 
product of pl5E in the intact virus (20). On SDS-PAGE, pl5E is slightly slower 
and pl2E  slightly faster in  mobility than the internal p15. In the M-MuSV 
system,  Witte  et al.  (21) provided evidence that  a  surface protein of 14,000 
daltons (on SDS-PAGE) with an isoelectric point of 4.4-4.6, is disulfide linked to 
gp70. Whether this protein corresponds to pl5E or pl2E of the R-MuLV system 
remains to be established. Much less is known about surface proteins and their 
precursors in M-MuLV,  the virus predominantly used in this study. However, 
since viruses in the Friend-Moloney-Rauscher  group are closely related (17), it 
seems safe to assume that the results obtained with one member of the group 
apply in general to all of them. 852  C1  RECEPTOR  ON  ONCORNAVIRUSES 
Our results of trypsin digestion of intact virus show unequivocally that the 
isolated C1 receptor on M-MuLV  is a surface protein. The receptor has a pl of 
about 7.5 as determined by IEF and co-migrates with the p15 complex on SDS- 
PAGE, well separated from p12 and pl0. Only p15E contains methionine while 
p15 does not (19),  and thus, p15E should be susceptible to cyanogen bromide 
cleavage. Treatment of  the isolated  receptor with cyanogen bromide cleaves the 
protein. For these reasons we identify  the receptor as p15E. It is quite possible 
that R-MuLV  p12E, if  it is derived from p15E, can also  activate complement. 
Indeed we have observed that complement  activation is not lost when  the 
receptor is cleaved by aging. Whether precursor proteins of p15, such as p60 
(22) or of p15E, such as Pr2a +  b  (20),  can also activate complement  is not 
known with certainty, although we have found that one p60 preparation from 
M-MuSV  did consume complement  (A. F. Esser and G. F. Vande Woude, un- 
published observations). However, in the latter  case complement consumption 
was not restricted  to human  serum, guinea pig serum was also  depleted. 
Summary 
Moloney leukemia virus activated both the classical and alternative pathways 
of human complement. About 500,000 virions were required to detect activation 
of the classical pathway whereas 5,000 times as many virions were necessary to 
initiate the alternative pathway, indicating that in this system only the former 
is of biological significance.  Disruption of the virus with Triton X-100 destroyed 
its  ability to initiate  the  alternative  pathway without  affecting its  ability to 
activate the classical pathway. After ultracentrifugation  of disrupted virus the 
active  component  could  be  recovered  in  the  supernate  and  was  isolated  by 
isoelectric focusing in granulated gels. Sodium dode~l sulfate-polyacrylamide gel 
electrophoretic analysis and cyanogen bromide digestion studies revealed that 
the activity resided in a  methionine-containing protein having a pI of 7.5 and a 
molecular  weight  of ----15,000 daltons.  The  purified  protein  interacts  strongly 
with  Clq  and  efficiently  activates  C1.  RNase  and  lipolytic  enzymes  had  no 
effect on the  isolated  protein  but incubation  with trypsin  resulted  in  loss of 
activity. Enzymatic digestion studies of surface-labeled virus indicate that the 
active protein is a  viral membrane protein.  On the basis of these results it is 
concluded  that  the  complement  receptor  of Moloney  leukemia  virus  is  the 
surface protein plSE. 
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